ArriVent BioPharma, Inc. AVBP Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $129.68M+5.2% | $153.35M+94.1% | $141.34M+79.2% | $129.26M+77.0% | $123.32M+72.2% | ||
| $27.19M+59.1% | $24.18M+58.0% | $21.08M+41.7% | $19.07M+44.9% | $17.09M+49.0% | ||
| $156.87M+11.7% | $177.53M+88.2% | $162.42M+73.3% | $148.33M+72.1% | $140.41M+69.0% | ||
| -$156.87M-11.7% | -$177.53M-88.2% | -$162.42M-73.3% | -$148.33M-72.1% | -$140.41M-69.0% | ||
| -$145.24M-14.0% | -$166.31M-107% | -$151.4M-86.8% | -$136.98M-82.9% | -$127.46M-70.9% | ||
| -$3.47+8.0% | -$4.41-71.6% | -$4.24+56.1% | -$4.02+72.4% | -$3.77+84.7% | ||
| -$159.7M— | -$180.56M— | —— | —— | —— | ||
| -$156.87M-11.7% | -$177.53M-88.2% | -$162.42M-73.3% | -$148.33M-72.1% | -$140.41M-69.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does ArriVent BioPharma, Inc.'s income statement data come from?
- Every line is extracted from ArriVent BioPharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.